- Home
- ACRS vs NRGV Comparison
ACRS vs NRGV Comparison
Compare ACRS & NRGV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- NRGV
- Stock Information
- Founded
- ACRS 2012
- NRGV 2017
- Country
- ACRS United States
- NRGV United States
- Employees
- ACRS N/A
- NRGV N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- NRGV Industrial Machinery/Components
- Sector
- ACRS Health Care
- NRGV Miscellaneous
- Exchange
- ACRS Nasdaq
- NRGV Nasdaq
- Market Cap
- ACRS 165.7M
- NRGV 133.4M
- IPO Year
- ACRS 2015
- NRGV N/A
- Fundamental
- Price
- ACRS $1.95
- NRGV $2.29
- Analyst Decision
- ACRS Strong Buy
- NRGV Buy
- Analyst Count
- ACRS 9
- NRGV 3
- Target Price
- ACRS $9.25
- NRGV $1.58
- AVG Volume (30 Days)
- ACRS 891.2K
- NRGV 2.0M
- Earning Date
- ACRS 11-05-2025
- NRGV 11-11-2025
- Dividend Yield
- ACRS N/A
- NRGV N/A
- EPS Growth
- ACRS N/A
- NRGV N/A
- EPS
- ACRS N/A
- NRGV N/A
- Revenue
- ACRS $16,789,000.00
- NRGV $51,716,000.00
- Revenue This Year
- ACRS N/A
- NRGV $314.58
- Revenue Next Year
- ACRS N/A
- NRGV $39.00
- P/E Ratio
- ACRS N/A
- NRGV N/A
- Revenue Growth
- ACRS N/A
- NRGV N/A
- 52 Week Low
- ACRS $1.05
- NRGV $0.60
- 52 Week High
- ACRS $5.17
- NRGV $2.70
- Technical
- Relative Strength Index (RSI)
- ACRS 56.76
- NRGV 70.49
- Support Level
- ACRS $2.01
- NRGV $1.73
- Resistance Level
- ACRS $2.16
- NRGV $2.33
- Average True Range (ATR)
- ACRS 0.10
- NRGV 0.18
- MACD
- ACRS -0.01
- NRGV 0.00
- Stochastic Oscillator
- ACRS 47.44
- NRGV 94.12
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.